NEW YORK (Reuters Health)—New recommendations from the National Psoriasis Foundation Medical Board suggest that losing weight by following a low-calorie diet can reduce psoriasisseverity in overweight patients, but there is little evidence to support other dietary interventions. “Our psoriasis patients have long asked us about the role of diet on psoriasis,” Dr. April Armstrong of the…
Articles by Cindy Devone-Pacheco
Disease-Modifying Antirheumatic Drugs Cut RA Risk
NEW YORK (Reuters Health)—Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report. Several studies have suggested that conventional or biological DMARDs might interfere with the pathogenic process and prevent more established forms of RA, but it remains unclear whether these drugs are…
AMA House of Delegates 2018 Annual Meeting Recap
On June 8–13, the AMA House of Delegates (HOD) came together in Chicago for its 2018 Annual Meeting. With the recent change in apportionment of geographic and specialty delegates now equal to each other, more than 600 members of the HOD were present, with several hundred staff and attendees from the AMA and other medical…
Targeted Rheumatoid Arthritis Treatment Does Not Improve Mental Health
NEW YORK (Reuters Health)—Effective pharmacotherapy of rheumatoid arthritis (RA) is not associated with meaningful improvements in mental health, according to a systematic review and meta-analysis. “We were surprised by the small effect sizes for mental-health outcomes across all of the treatments included in this review, but particularly for the anti-TNF versus disease-modifying antirheumatic drug (DMARD)…
Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial
(Reuters)—Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year. The data come two weeks after U.S. health regulators approved the drug, baricitinib, under the trade name Olumiant, with a far more restrictive label…
ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed
Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s…
Spine Surgery May not Be Needed to Ease Back Pain from Osteoporosis
(Reuters Health)—Patients with acute pain from osteoporosis damage to the spine don’t experience any more relief from surgery to inject cement into cracked or broken vertebrae than they would with a sham procedure, a recent trial in The Netherlands suggests. All of the patients in the experiment had compression fractures, which can happen when osteoporosis…
FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease
(Reuters)—The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc’s drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis. The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent…
Trump Says Drug Companies to Announce “Massive” Price Cuts Soon
WASHINGTON (Reuters)—President Donald Trump on Wednesday said he expects major drug companies to slash prices on their products in two weeks, but did not provide details on which companies would do so or how such reductions would be made. Health care lobbyists in Washington said they were caught by surprise and had no idea what…
Gap in Regulating Biotech Drug Copies Prompts WHO to Step In
LONDON (Reuters)—Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike -but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 28
- Next Page »